Cargando…
Determinants of tumor treating field usage in patients with primary glioblastoma: A single institutional experience
BACKGROUND: Determinates of tumor treating fields (TTFields) usage in patients receiving combined modality therapy for primary IDH wild-type glioblastoma are currently unknown. METHODS: Ninety-one patients underwent maximal debulking surgical resection, completed external beam radiotherapy with conc...
Autores principales: | Ballo, Matthew T, Qualls, Kaitlin W, Michael, L Madison, Sorenson, Jeffrey M, Baughman, Brandon, Karri-Wellikoff, Saradasri, Pandey, Manjari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555297/ https://www.ncbi.nlm.nih.gov/pubmed/36249289 http://dx.doi.org/10.1093/noajnl/vdac150 |
Ejemplares similares
-
Current usage of tumor treating fields for glioblastoma
por: Lassman, Andrew B, et al.
Publicado: (2020) -
Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma
por: Nguyen, Ngan, et al.
Publicado: (2021) -
Integration of Tumor‐Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies
por: Wang, Yuefeng, et al.
Publicado: (2019) -
Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields
por: Pandey, Manjari, et al.
Publicado: (2022) -
Managing Massive Splenic Hematoma: Exploratory Laparotomy or Active Surveillance?
por: Otieno, Steve B, et al.
Publicado: (2021)